Barclays’s Vor Biopharma VOR Stock Holding History

Barclays’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$268K	Buy	14,565 +14,429	+10,610%	+$218K	﹤0.01%	3549
2026 Q1	$2.43K	Sell	136 -1,263	-90%	-$17.8K	﹤0.01%	4835
2025 Q4	$18.3K	Buy	+1,399	New	+$26.1K	﹤0.01%	4879
2025 Q2	–	Sell	-4,987	Closed	-$71.6K	–	5558
2025 Q1	$71.6K	Buy	4,987 +4,436	+805%	+$107K	﹤0.01%	4511
2024 Q4	$12.2K	Hold	551	–	–	﹤0.01%	4973
2024 Q3	$7.72K	Sell	551 -737	-57%	-$13.4K	﹤0.01%	4997
2024 Q2	$25.8K	Sell	1,288 -636	-33%	-$20.6K	﹤0.01%	4393
2024 Q1	$91.2K	Sell	1,924 -680	-26%	-$29.9K	﹤0.01%	4463
2023 Q4	$117K	Buy	2,604 +2,243	+621%	+$92.6K	﹤0.01%	4602
2023 Q3	$15.3K	Sell	361 -17	-4%	-$922	﹤0.01%	4228
2023 Q2	$23.3K	Buy	+378	New	+$34.5K	﹤0.01%	4105
2022 Q2	–	Sell	-154	Closed	-$19K	–	5287
2022 Q1	$19K	Buy	+154	New	+$26.2K	﹤0.01%	4465

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Barclays's VOR Position: Q2 2026 in Review

Barclays increased its Vor Biopharma (VOR) stake by 10,610% in Q2 2026, buying an estimated $218K and bringing the position to 14,565 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #3549.

Barclays first reported a position in VOR in Q1 2022 and has held it in 12 quarters since. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

Barclays held 14,565 shares of Vor Biopharma worth $268K as of Q2 2026.
Barclays bought 14,429 Vor Biopharma shares in Q2 2026, an estimated $218K.
Vor Biopharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3549 holding.
Barclays first reported a position in Vor Biopharma in Q1 2022 and has held it in 12 quarters since.
102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.